Jane Larkindale, DPhil, is the Executive Director for the Duchenne Regulatory Science Consortium at the Critical Path Institute in Tucson, Arizona, concurrently serving as the Vice President for Research Development at the Friedreich’s Ataxia Research Alliance. She is a molecular biologist by training, having completed her DPhil (PhD) in the department of plant sciences at Oxford University in 2001, which she attended on a Rhodes scholarship. In the laboratory, she did research in areas as diverse as molecular biology, biochemistry, genomics, plant science, medical physics, marine biology, and industrial chemistry. In the course of this research, she published numerous original research papers and review articles in several disciplines. Her experience in drug development and neuromuscular diseases started at the Muscular Dystrophy Association, an international non-profit covering over forty neuromuscular diseases, where she worked from 2007 to 2014, finally as Vice President for Research. Dr. Larkindale was instrumental in the startup of MDA Venture Philanthropy (MDA’s drug development arm), which invested in 21 drug development projects, of which ten are in or about to start clinical trials, and several of which have been licensed by large pharmaceutical companies. She led an organization-wide strategic planning process for research, and initiated and organized MDA’s annual meeting series, which attracts over 500 participants annually. In her free time, Dr. Larkindale is a volunteer for the Southern Arizona Rescue Association, taking part in search-and-rescue missions across Pima County. She enjoys all outdoor activities, particularly trail running and backpacking.